As you are no doubt aware, ACT is quickly evolving from a development-stage biotechnology company to a clinical-stage company developing regenerative medicine. We now have two of the three total FDA clearances for embryonic stem cell-based clinical trials that have ever been issued, and we are eagerly anticipating starting these trials in the first half of this year.
Since the two clinical trials are likely to garner a lot of media attention, we have decided to retain the services of Russo Partners. In business for 23 years, Russo Partners is the best-in-breed of healthcare and life science PR/corporate communications firms. As an added benefit, Russo Partners (formerly Noonan Russo) worked with ACT during an earlier era (2000 – 2001), so knows the company well.
We are pleased to have Russo Partners on board and look forward to their assistance as we share major future developments.
Interim Chairman and CEO
Advanced Cell Technology, Inc.